CYCN 外匯新聞
Cyclerion Gets FDA Orphan Drug Designation For Zagociguat For Mitochondrial Diseases
Biopharmaceutical company Cyclerion Therapeutics, Inc. (CYCN) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to zagociguat (previously CY6463) for the treatment of mitochondrial diseases.
RTTNews
|
704天前
